Received FDA authorization and recorded first commercial sales of ARC-EX System Secured strategic investment from Ottobock ...

Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ETCompany ParticipantsAdanna Alexander – IRPhillip Chan - ...

Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in ...

BEIJING, CHINA / ACCESS Newswire / March 31, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and ...

Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s Disease ...

Federal judges dealt twin blows to President Trump’s retaliation campaign on Friday by issuing temporary restraining orders ...

Revenues Increased by 51%, Gross Profit Increased by 82% and Net Loss Reduced by 54% for the Year Ended December 31, 2024Rehovot, Israel, March ...

College admissions officers are increasingly looking for applicants with demonstrated leadership skills, impactful ...

Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...

Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food and Drug Administration (FDA) ...

Federal workers are already bracing for major new cuts. Mr. Trump signed an executive order aimed at dismantling the ...

New Drug Application (NDA) for LNZ100 for treatment ... today reported financial results for the fourth quarter and full year ended December 31, 2024, and recent corporate highlights. “This year has ...